Aptose Biosciences (NASDAQ:APTO) and aTyr Pharma (NASDAQ:LIFE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
This table compares Aptose Biosciences and aTyr Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Aptose Biosciences and aTyr Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aptose Biosciences currently has a consensus target price of $6.40, indicating a potential upside of 123.00%. aTyr Pharma has a consensus target price of $16.57, indicating a potential upside of 217.37%. Given aTyr Pharma’s higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Aptose Biosciences.
Institutional & Insider Ownership
5.9% of Aptose Biosciences shares are held by institutional investors. 7.3% of Aptose Biosciences shares are held by company insiders. Comparatively, 27.7% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Aptose Biosciences has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.
Earnings & Valuation
This table compares Aptose Biosciences and aTyr Pharma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aptose Biosciences||N/A||N/A||-$28.87 million||($0.86)||-3.34|
|aTyr Pharma||N/A||N/A||-$34.51 million||($16.11)||-0.32|
Aptose Biosciences is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
About aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.